SCHEMBL1591789

SCHEMBL1591789

NS(=O)(=O)c1ccccc1Oc1ccnc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 10/20 0.47
CA9 Q16790 10/20 0.47
CA12 O43570 8/20 0.47
CA14 Q9ULX7 4/20 0.47
CA1 P00915 9/20 0.44
NCF1 P14598 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.39
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
PTK2B Q14289 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FTO Q9C0B1 1/20 0.37
MAPK1 P28482 1/20 0.36
BRAF P15056 1/20 0.36
KDR P35968 1/20 0.36
MAPK14 Q16539 1/20 0.36
TNNI3K Q59H18 1/20 0.36
AXL P30530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9431770 0.80 NCF1 (0.54) NCF1LOXL2NPC1TP53MAPT
SCHEMBL10529086 0.79 CA2 (0.54) CA2CA9CA12CA14CA1
SCHEMBL27462646 0.77 NCF1 (0.52) CA2CA9CA12CA1NCF1
SCHEMBL1591720 0.76 NCF1 (0.56) NCF1LOXL2NPC1TP53MAPT
SCHEMBL4472632 0.76 KDM4E (0.43) NCF1LOXL2NPC1TP53MAPT
SCHEMBL27665935 0.73 PDGFRB (0.49) CA2CA9CA12CA14CA1
SCHEMBL4766092 0.73 RAB9A (0.46) NCF1LOXL2NPC1RAB9ASMN1; SMN2
SCHEMBL1626273 0.73 CA2 (0.56) CA2CA9CA12CA1NPC1
SCHEMBL6220265 0.72 P2RX4 (0.49) CA2CA9CA12CA14CA1
SCHEMBL14333771 0.72 LOXL2 (0.51) CA2CA9CA12CA14CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 US disclosed
EP-2262772-B1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2012-07-18 EP disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 US disclosed
EP-2262772-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2010-12-22 EP disclosed
WO-2009127417-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS AXL, FLT3, TYRO3 CA2 4102/4885CA9 4799/4885CA12 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.